SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: A phase 1 trial

Authors

• Lauren Averett Byers, University of Texas MD Anderson Cancer Center
• Daniel Morgensztern, Washington University School of Medicine in St. Louis
• et al.

Journal

Nature Medicine

Publication Date

8-1-2026

Volume

32

Issue

8

First Page

2898

Last Page

2908

Document Type

Open Access Publication

DOI

10.1038/s41591-026-04452-0

Rights and Permissions

Byers, L.A., Cho, B.C., Cooper, A.J. et al. SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial. Nat Med 32, 2898–2908 (2026). https://doi.org/10.1038/s41591-026-04452-0 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Recommended Citation

Byers, Lauren Averett; Morgensztern, Daniel; and et al., "SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: A phase 1 trial." Nature Medicine. 32, 8. 2898 - 2908. (2026).
https://digitalcommons.wustl.edu/oa_4/7569

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.